Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a non-brokered private placement of up to 30 Class A multiple voting shares at a price of $25 per share, for gross proceeds of up to $750. The offering, which was approved by shareholders on September 26, 2025, is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz. Upon completion, the voting rights attached to the Class A shares will increase to 75.27%, restoring them to nearly their original level when the company went public in 2018. The proceeds from the placement will be used for general working capital purposes.
This announcement is significant because it reinforces the control structure of Quantum BioPharma, potentially affecting corporate governance and strategic decision-making. The increase in voting rights for the Class A shares suggests that the company's leadership intends to consolidate control, which could influence future directions in research and development. Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for treating challenging neurodegenerative, metabolic, and alcohol misuse disorders. Its lead compound, Lucid-MS, is a patented new chemical entity that has shown promise in preclinical models for preventing and reversing myelin degradation, the underlying mechanism of multiple sclerosis.
Additionally, through its subsidiary Lucid Psycheceuticals Inc., the company is advancing research in this area. Quantum BioPharma also invented unbuzzd(TM) and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 20.11% ownership stake as of March 31, 2025. The agreement includes royalty payments of 7% of sales from unbuzzd(TM) until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses. Furthermore, Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
For more details on the private placement, the full press release is available at https://ibn.fm/aicDo. Investors seeking the latest updates on QNTM can visit the company's newsroom at https://ibn.fm/QNTM. This development underscores the company's ongoing efforts to secure funding for its operations and maintain strategic control as it continues to develop treatments for serious medical conditions.
